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 Abstract    
Objective: The polycystic ovary syndrome (PCOS) is known to be related with increased metabolic and car-
diovascular risks. Various phenotypic subgroups of PCOS have been proven to have metabolic and endocrine 
disorders with varying degrees of severity. However, intra-renal vascular resistance, which is an indirect indication of 
atherosclerosis, remains unknown in PCOS subgroups. In this study we examined whether PCOS subgroups have 
different intra-renal resistance symptoms. 
Material and Methods: 98 PCOS patients (diagnosed according to the Rotterdam criteria) 30 controls were 
included in the study. The diagnosis of PCOS was established in the presence of at least two of the following cri-
teria: 1- oligo and/or amenorrhea (OM); 2- clinic and/or biochemical signs of hyperandrogenism (HA); 3- polycystic 
ovarian morphology (PCO) detected by transvaginal ultrasonography. 37 patients (Group 1) met all three criteria 
(HA+OM+PCO), 29 patients (Group 2) met two of the criteria including hyperandrogenism (HA+OM or HA+PCO) 
and the remaining 32 patients (Group 3) had no hyperandrogenism but fulfilled the other two criteria; PCO+OM. 
Renal Doppler ultrasonography and hormonal/ biochemical analyses were carried out. The first outcome measure 
was designated as the differences in the renal resistive index (RRI) values of the groups, and the second outcome 
measure was designated as the relation of RRI with the insulin resistance and lipid profile.
Results: In Group 1, the RRI and the homeostasis model assessment of insulin resistance (HOMA-IR) values were 
significantly higher than in Group 3 and controls (P < 0.031, P < 0.001, respectively, after adjusting for age and 
BMI). The RRI and HOMA-IR values in Group 3 were similar to those of the control group. It was determined that 
RRI has a positive correlation with HOMA-IR (r=0.784, P<.0001) and BMI (r=0.645, P<.0001).   
Conclusions: In this study, we demonstrated that PCOS subgroups have metabolic and endocrine disorders and 
cardiovascular risks of varying degrees of severity. Moreover, we showed that there was no increase of metabolic 
and cardiovascular risks in PCOS patients without hyperandrogenism. 
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Introduction
Polycystic	Ovary	Syndrome	(PCOS),	which	is	characterized	
by	 oligomenorrhea	 and	 hyperandrogenism,	 is	 the	most	 widely	
encountered	endocrine	pathology	among	women	of	reproductive	
age.	The	prevalence	of	PCOS,	 the	diagnostic	 criteria	of	which	
remain	 a	 source	 of	 controversy,	 is	 6-8%	 [1]	 according	 to	NIH	
and	 18%	 according	 to	 the	 Rotterdam	 diagnostic	 criteria.	 In	
contrast	 to	 the	Androgen	Excess	Society	 (AES),	which	accepts	
hyperandrogenism	as	an	essential	characteristic	of	PCOS,	a	new	
phenotypic	 subgroup	 of	 PCOS	 without	 hyperandrogenism	 has	
been	 defined	 according	 to	 the	 expanded	 diagnostic	 criteria	 of	
Rotterdam	[3].			
Most	women	with	PCOS	have	certain	metabolic	disorders	
along	 with	 their	 endocrine	 disorders	 [4].	 The	 most	 important	
metabolic	 disorders	 include	 insulin	 resistance	 (IR),	 which	
results	 in	 hyperinsulinemia,	 and	 atherogenic	 dyslipidemia	 [5].	
Literature	 reports	 that	 50-70%	 of	 all	women	with	 PCOS	 have	
varying	degrees	of	insulin	resistance	[6,	7].	If	hyperandrogenism	
is	used	as	a	diagnostic	criterion	for	PCOS,	insulin	resistance	and	
hyperinsulinemia	are	encountered	much	more	frequently	[8].	 It	
has	been	 shown	 in	 studies	 so	 far	 that	metabolic	 syndrome	and	
insulin	resistance	are	encountered	significantly	less	frequently	in	
PCOS	patients	who	are	normoandrogenic	[9,	10].	
Renal	 resistive	 index	 (RRI)	 reflects	 the	 renovascular	
resistance,	which	 is	 an	 early	marker	 of	 vascular	 damage.	 RRI	
is	 accepted	 as	 a	 reliable	 marker	 for	 atherosclerosis	 [11].	 The	
increase	in	RRI	displays	a	significant	correlation	with	the	severity	
of	systemic	atherosclerosis	[12].	The	correlation	between	insulin	
resistance	and	RRI	has	been	demonstrated	in	patients	with	type-2	
diabetes	and	metabolic	syndrome	[11,	13].	
The	metabolic	and	cardiovascular	effects	of	PCOS	are	hotly	
debated	 today.	Although	 there	 is	 no	 conclusive	 evidence	 that	
PCOS	increases	the	risk	of	atherosclerosis	[14],	it	has	been	shown	
that	most	of	the	clinical	and	subclinical	markers	of	atherosclerosis	
are	altered	in	patients	with	PCOS	[15,	16].	The	state	of	the	intra-
renal	 vascular	 resistances,	 which	 is	 an	 indirect	 indication	 of	
atherosclerosis,	remains	unknown	in	PCOS	subgroups.
In	this	study	we	compared	intra-renal	resistance	symptoms	
of	PCOS	phenotypic	subgroups.	Moreover,	the	relation	between	
renal	resistive	index	and	insulin	resistance	was	examined.	
Material and Methods
The	patients	were	selected	from	amongst	those	who	presented	
at	 the	 infertility	 polyclinic	 of	 Baskent	 University	 Hospital,	
Konya.	The	suitability	for	inclusion	in	the	study	was	evaluated	in	
120	patients	diagnosed	with	PCOS	according	to	the	Rotterdam.	
22	patients	were	excluded:	16	did	not	meet	the	suitability	criteria,	
and	6	who	refused	to	take	part.	The	remaining	98	women	with	
PCOS	 were	 included	 in	 the	 study.	 For	 the	 control	 group,	 35	
women	with	infertility	reasons	other	than	PCOS	were	evaluated	
for	their	suitability	in	the	study.	Three	of	these	did	not	satisfy	the	
necessary	criteria	and	2	refused	to	participate.	The	remaining	30	
patients	were	included	in	the	study	as	controls.
In	 accordance	 with	 the	 Rotterdam	 criteria,	 the	 diagnosis	
of	PCOS	was	established	in	 the	presence	of	at	 least	 two	of	 the	
following	three	criteria:	
1	–		oligo	and/or	amenorrhea	(OM);
2	–		clinic	and/or	biochemical	signs	of	hyperandrogenism	
(HA);	
 Streszczenie 
Cel pracy: Zespół policystycznych jajników jest związany ze zwiększonym ryzykiem metabolicznym i sercowo-
naczyniowym. Fenotypowe podgrupy w obrębie zespołu PCO charakteryzują się zaburzeniami metabolicznymi i 
endokrynnymi o różnym stopniu nasilenia. Jednak wewnątrznerkowa oporność naczyniowa, która jest pośrednim 
wykładnikiem miażdżycy, pozostaje nieznana w podgrupach zespołu PCO. W badaniu ocenialiśmy czy podgrupy 
zespołu PCO mają różne objawy wewnątrznerkowej oporności.
Materiał i metoda: do badania włączono 98 pacjentek z zespołem PCO (zdiagnozowanym według 
kryterium z Rotterdamu) oraz 30 pacjentek kontrolnych. Rozpoznanie zespołu PCO postawiono na podstawie 
obecności przynajmniej dwóch z poniżej wymienionych kryteriów: 1-oligo i/lub amenorrhea (OM); 2-kliniczne 
lub biochemiczne objawy hiperandrogenizmu (HA); 3-policystyczny obraz jajników (PCO) w przezpochwowym 
badaniu ultrasonograficznym. Grupę 1 stanowiło 37 pacjentek, które spełniły wszystkie kryteria diagnostyczne 
(HA+OM+PCO), grupa 2 to 29 pacjentek z dwoma kryteriami, w tym kryterium hiperandrogenizmu (HA+OM lub 
HA+PCO), pozostałe 32 pacjentki to grupa 3 – bez hiperandrogenizmu ale z dwoma pozostałymi kryteriami; 
PCO+OM. Przeprowadzono badanie dopplerowskie nerek i hormonalno-biochemiczną ocenę. Jako pierwszą 
zmierzono różnicę pomiędzy grupami w indeksie oporu nerkowego (RRI), następnie oceniono związek pomiędzy 
RRI a insulinoopornością i profilem lipidowym.
Wyniki: W grupie 1, RRI i wskaźnik oceny insulinooporności (HOMA-IR) były istotnie wyższe niż w grupie 3 oraz 
kontrolnej (p<0.031, p<0.001, odpowiednio po uwzględnieniu wieku i BMI). W grupie 3 i kontrolnej uzyskano 
podobne wyniki RRI i HOMA-IR. Znaleziono pozytywną korelację RRI z HOMA-IR (r=0.784, p<0.0001) oraz BMI 
(r=0.645, p<0.0001).
Wnioski: W naszym badaniu wykazaliśmy, że podgrupy zespołu PCO charakteryzują się zaburzeniami 
metabolicznymi i ryzykiem sercowonaczyniowym o różnym nasileniu. Co więcej, u pacjentek z zespołem PCO bez 
hiperandrogenizmu nie wystapiło nasilenie ryzyka metabolicznego i sercowonaczyniowego.
 Słowa kluczowe: zespół policystycznych jajników / fenotypy zespołu PCO / 
      / insulinooporność / wskaźnik oporu nerkowego / 
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3	–		polycystic	 ovarian	 morphology	 (PCO)	 detected	 by	
transvaginal	ultrasonography.	
37	of	the	98	POCS	patients	(Group	1)	met	all	three	criteria	
(HA+OM+PCO),	29	patients	(Group	2)	met	 two	of	 the	criteria	
including	 hyperandrogenism	 (HA+OM	 or	 HA+PCO)	 and	 the	
remaining	32	patients	 (Group	3)	had	no	hyperandrogenism	but	
fulfilled	the	other	two	criteria;	PCO+OM.	
In	 this	 case-controlled	 study,	 the	 women	 with	 PCOS,	
separated	into	phenotypic	subgroups	according	to	the	Rotterdam	
criteria,	 were	 compared	 with	 those	 in	 the	 control	 group	 with	
regard	to	their	intra-renal	vascular	and	insulin	resistances,	as	well	
as	lipid	profiles.	The	first	measure	of	result	was	designated	as	the	
differences	in	the	renal	resistive	index	(RRI)	values	of	the	groups,	
and	the	second	measure	of	result	was	designated	as	the	relation	of	
RRI	with	the	insulin	resistance	and	lipid	profile.	The	number	of	
cases	was	determined	through	power	analysis.
The	criteria	for	inclusion	in	the	study	were:	19-37	years	of	
age,	19-40	BMI,	no	history	of	endocrine	diseases	such	as	type-2	
DM	or	hyperprolactinemia,	no	hypertension,	no	medical	treatment	
for	PCOS	(Ocs,	antiandrogenics,	insulin	sentisizers,	antiplatelets)	
in	the	last	three	months	before	the	study.	Smokers,	pregnant	or	
breastfeeding	women	were	also	excluded	from	the	study.	
The	diagnosis	of	PCOS	was	made	according	to	the	criteria	
of	 the	 Rotterdam	 ESHRE/ASRM-sponsored	 PCOS	 consensus	
workshop	group	(2004).	
With	 the	 exclusion	 of	 other	 conditions	 that	 could	 cause	
menstrual	 irregularity	 and	 androgen	 excess,	 patients	 who	
presented	with	 two	 out	 of	 three	 of	 the	 following	 criteria	were	
diagnosed	with	PCOS:	
1	–	 oligo	and/or	anovulation	(menstrual	cycle	between	35-
50	days	or	secondary	amenorrhea	and/or	anovulation);	
2	–	 clinic	 and/or	 biochemical	 signs	 of	 hyperandrogenism	
[Ferriman-Gallway	modified	score	≥8	and/or	acne,	and	
/or	 hyperandrogenemia:	 total	 testosterone	 >0,6	 ng/ml	 
(2	nmol/l);	
3	–	 polycystic	 ovaries,	 identified	 by	 transvaginal	
ultrasonography	 (presence	 of	 ≥12	 follicles	 in	 each	
ovary,	measuring	2-9	mm	in	diameter	and/or	increased	
ovarian	volume	>10cm³)	[17].	
Insulin	resistance	was	calculated	using	the	homeostasis	model	
assessment	of	insulin	resistance	(HOMA-IR),	with	the	following	
equation:	HOMA-IR	=	 [(fasting	glucose	 in	mg/	dL	x	0.05551)	
x	 fasting	 insulin	 in	 µU/mL]	 /22.5	 [18].	 Waist	 circumference	
was	measured	 at	 the	 umbilicus	 and	 the	 hip	 circumference	was	
measured	at	the	most	prominent	buttock	level.	The	waist-to-hip	
ratio	was	considered	to	be	the	measure	of	body	fat	distribution.
In	this	study,	the	renal	Doppler	ultrasonography	was	carried	
out	 by	 a	 single	 diagnostic	 medical	 sonographer	 who	 had	 no	
information	about	 the	clinical	state	of	 the	patients.	All	subjects	
had	normal	kidney	functions.	Patient	anamneses	confirmed	they	
had	 not	 consumed	 drinks	with	 caffeine	 or	 alcohol,	 smoked	 or	
performed	heavy	exercise	in	the	last	24	hours	before	the	test.	The	
Doppler	examination	was	carried	out	in	the	morning	after	a	night	
of	fasting	and	following	a	30-minute	rest.	
The	ultrasonographic	examination	was	carried	out	by	means	
of	 an	 ultrasound	 device	 with	 a	 duplex	 Doppler	 and	 B-mode	
apparatus	 equipped	 with	 a	 5	 MHz	 convex	 probe	 (Sonoline	
Antares,	Siemens,	Germany).	RRI	of	each	patient	was	calculated	
by	taking	the	mean	of	the	three	separate	measurements	made	at	
the	level	of	the	interlobar	arteries	for	each	kidney:	peak	systolic	
speed	–	end	diastolic	speed	/	peak	systolic	speed	[19].	
All	the	blood	samples	were	collected	after	a	night	of	fasting.	
The	hormonal	and	biochemical	examination	of	the	samples	was	
performed	on	the	same	day	as	the	ultrasonographic	examination.	
Fasting	 glucose,	 high-density	 lipoprotein	 [HDL]	 cholesterol,	
low-density	 lipoprotein	 [LDL]	 cholesterol,	 triglyceride	 levels	
were	 measured	 with	 original	 kits,	 using	 an	 Abbott-Aeroset	
autoanalyzer	 (Chicago,	 IL,	 USA).	 Serum	 levels	 of	 luteinizing	
hormone	 [LH]	 and	 insulin	 were	 measured	 by	 a	 microparticle	
enzyme	 immunoassay	 method	 in	 an	 AXSYM	 autoanalyzer	
(Abbott	 Laboratories,	 IL,	 USA).	 Serum	 total	 testosterone	 and	
thyroid	 stimulating	 hormone	 levels	were	measured	 by	 a	 solid-
phase	competitive	chemiluminescent	enzyme	immunoassay	in	an	
Immulite	2000	autoanalyzer	using	BIODPC	reagents	(Bio	DPC,	
Los	Angeles,	CA,	USA).	
After	the	Ethical	Committee	of	Baskent	University	confirmed	
the	working	protocol,	the	written	informed	consent	was	obtained	
from	the	patients.
Statistical analyses
Statistical	analyses	were	performed	using	SPSS	10.0	(SPSS	
for	Windows	10.0;	Chicago,	IL,	USA).	The	ANOVA	test	was	used	
to	 investigate	whether	 there	were	 any	 differences	 between	 the	
groups.	Normality	of	the	data	was	evaluated	by	the	Kolmogorov-
Smirnov	 test	 with	 Lilliefors	 correction.	 Differences	 among	
the	groups	were	 assessed	by	 the	 t-test	 for	normally	distributed	
continuous	 variables	 and	 by	 the	Mann-Whitney	 U	 test	 with	 a	
Bonferroni	 correction	 for	 non-normally	 distributed	 continuous	
variables.	
Due	to	age	and	BMI	influence	on	the	fasting	insulin	and	lipid	
profiles,	analyses	were	optionally	adjusted	for	age	and	BMI.	A	
p-value	<	0.05	was	 considered	 significant.	The	 correlation	 test	
necessary	 for	 the	 second	 hypothesis	was	 carried	 out	 using	 the	
Pearson’s	correlation	analysis.
Results
The	 clinical	 features,	 metabolic	 and	 hormonal	 states	 and	
renal	Doppler	parameters	of	 the	patients	 are	 shown	 in	Table	 I.	
There	turned	out	to	be	statistically	significant	differences	between	
the	groups	in	their	RRI,	PSV,	HOMA	IR	and	lipid	profile	values	
when	these	were	subjected	to	the	one-way	ANOVA	test.	In	those	
PCOS	patients	with	all	three	criteria	(Group	1),	RRI	and	HOMA	
IR	levels	were	higher	than	in	the	Group	3	PCOS	patients	without	
hyperandrogenism	 as	 well	 as	 in	 the	 control	 group	 (P	 <0.005,	
P	<0.001,	P <0.031,	 respectively,	 after	 adjustment	 for	 age	 and	
BMI).	In	Group	1	PCOS	patients	 the	AFC,	WHR,	LH,	insulin,	
total	testosterone	and	triglyceride	levels	were	higher	while	HDL	
was	lower	(Table	I).	
In	contrast,	between	2	and	3	PCOS	groups	on	one	hand	and	
the	 control	 group	 on	 the	 other,	 no	 difference	was	 observed	 in	
the	monitored	 variables	 (parameters)	 save	 for	 the	AFC.	When	
the	 variables	 of	 all	 the	 patients	 in	 the	 study	were	 subjected	 to	
correlation	analysis,	there	turned	out	to	be	a	significant	correlation	
between	the	RRI	and	HOMA	IR	(r	=	0.665,	P <0.000),	 insulin	 
(r	 =	 0.703,	P <0.000)	 and	 BMI	 values	 (r	 =	 0.555,	P <0.000)	
(Table	II).	
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Discussion
Diagnostic	symptoms	as	well	as	metabolic	and	cardiovascular	
effects	 of	 PCOS	 are	 still	 debated.	 Its	 phenotypic	 spectrum	
has	 been	 expanded	 through	 the	 Rotterdam	 criteria.	 After	 this	
change	 in	 the	diagnostic	 criteria,	metabolic	 anomalies	 came	 to	
be	observed	with	 less	frequency	and	severity	 in	patients	newly	
diagnosed	with	PCOS	[20].	PCOS	is	known	 to	be	 related	with	
deep	insulin	resistance,	which	is	accompanied	by	obesity,	as	well	
as	with	defects	in	insulin	secretion	[18].	It	is	thought	that	insulin	
resistance	 is	 the	 primary	 biochemical	 defect	 that	 lies	 beneath	
epidemic	obesity	accompanied	by	cardiovascular	disorders	and	
type-2	diabetes	[21].	Insulin	resistance	is	linked	with	upset	glucose	
metabolism	as	well	as	with	many	other	metabolic	anomalies	such	
as	dyslipidemia,	inflammation	and	hypercoagulability	[21].	It	is	
accepted	that	insulin	resistance	has	a	pathophysiological	role	in	
the	development	of	 a	 cardiometabolic	 state	 [22,	23].	 Increased	
atherosclerosis	 linked	with	 insulin	 resistance	 is	 a	 result	 of	 the	
vascular	effect	of	these	metabolic	anomalies	or	of	the	molecular	
pathology	linked	with	the	insulin	receptor	signal	[24].
It	is	not	fully	known	to	what	extent	the	phenotypic	subgroups	
in	PCOS	are	affected	by	cardiovascular	risks.	So	far	studies	have	
shown	that	insulin	resistance	is	higher	in	hyperandrogenic	than	
normoandrogenic	PCOS	patients	[9,	10,	22].	
Our	findings	represent	a	continuation	and	confirmation	of	the	
previous	studies	on	this	subject.	Our	study	has	shown	that	insulin	
resistance	 and	 intra-renal	 resistance	 are	 higher	 in	 the	 PCOS	
patients	with	all	three	criteria	than	in	the	PCOS	subgroup	without	
hyperandrogenism	as	well	as	in	the	control	group	(Table	I).	
We	also	demonstrated	the	existence	of	a	positive	correlation	
between	the	intra-renal	resistance	and	insulin	resistance	in	PCOS	
patients.
Intra-renal	 resistance	 reflects	 systemic	 vascular	 damage.	
Increased	 intra-renal	 resistance,	 at	 least	 in	 the	 early	 phase,	
can	 be	 taken	 as	 an	 indication	 of	 the	 functional	 and	 reversible	
modification	 of	 intra-renal	 vasoconstriction	 [25].	 Studies	 have	
shown	 that	RRI	 is	 increased	 in	patients	with	 insulin	 resistance	
as	well	as	in	those	with	type-2	diabetes,	hypertension	or	chronic	
kidney	failure	[11,	13].	
Table I. Clinical characteristics and endocrine, metabolic, renal Doppler parameters of PCOS phenotypic subgroups with the control group.
[PCO+HA+OM]
Grup1 
(n=37)
[HA+OM, 
HA+PCO]
Grup 2 
(n=29)
[PCO+OM] 
Grup 3 
(n=32)
Control group 
(n=30)
One-way 
ANOVA P- 
value*
One-way 
ANOVA  
P-value 
adjusted**  
Age (years) 25.5±4.7 25.27±2.29 26.1±3.0 27.3±4.1 0.068 -
BMI (kg/m2) 30.7±5.9 c 29.1±7.1 26.0±5.9 26.7±6.1 0.018 -
WHR 0.79±0.05 e 0.79±0.05 0.77±0.04 0.76±0.03 0.032 0.048
AFC 53.5±16.9 e 47.6±23.9d 54.8±35.3 b 20.3±5.8 <0.001 <0.001
RRI 0.66±0.03 e, c 0.64±0.04 0.63±0.04 0.62±0.04 0.006 0.031
PSV 87.7±17.5 e 99.3±8.05 94.5±21.6 101.3±21.9 0.013 0.015
Glucose (mg/dL) 96.79±9.14 e 93.41±6.15 94.00±5.84 92.26±4.46 0.025 0.024
Insulin (µU/mL) 14.90±6.29 a,c,e 9.80±6.12 10.19±6.35 10.34±4.84 <0.001 0.005
HOMA-IR 3.51±1.43 a,c,e 2.29±1.39 2.26±1.27 2.22±0.99 <0.001 0.001
HDL (mg/dL) 42.21±10.60 e,c 43.55±10.91d 49.11±7.71 52.04±7.40 0.004 0.019
LDL (mg/dL) 115.74±24.3a 103.68±33.7 101.94±23.8 96.26±15.7 0.012 0.016
Triglycerides  
(mg/dL) 
139.58±80.6 c e 113.32±74.9 96.78±42.4 102.26±37.1 0.034 0.096
Total Testosterone 
(ng/mL)
0.78±0.37 c,e 0.61±0.32 0.54±0.31 0.53±0.14 <0.001 <0.001
TSH (µU/mL) 5.20±11.89 4.86±6.29 2.47±1.95 1.89±1.75 0.358 0.171
LH (mIU/mL) 9.70±4.37 e 12.28±6.07 d 10.45±6.20 b 4.05±1.95 <0.001 0.001
PCO: polycystic ovaries; OM: oligo-or amenorrhea; HA: hyperandrogenism; ANOVA: analysis of variance; BMI: body mass index; WHR: waist-hip ratio; AFC: antral follicle 
count; RRI: renal resistive index; PSV: peak systolic velocity; HOMA-IR: homeostasis model assessment of insulin resistance; HDL: high-density lipoprotein; 
LDL: low-density lipoprotein; TSH: thyroid-stimulating hormone; LH: luteinizing hormone.
a [PCO+HA+OM] vs.[HA+OM, HA+PCO], b [PCO+OM] vs. Control, c [PCO+HA+OM] vs. [PCO+OM], d [HA+OM, HA+PCO] vs. Control, e [PCO+HA+OM] vs. Control. 
Analysis of variance (ANOVA) was used for differences between the groups. Pair-wise comparisons among the groups were assessed with the Mann-Whitney U test with 
Bonferroni correction. All values are given as mean±SD. p<0.05 was considered statistically significant.
* One-way ANOVA P-values (unadjusted) across the control group, [PCO+HA+OM], [HA+OM, HA+PCO], [PCO+OM] phenotypic subgroups.
** One-way ANOVA P- values (adjusted for age and BMI) across the control group, [PCO+HA+OM], [HA+OM, HA+PCO], [PCO+OM] phenotypic subgroups.
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In	obese	or	overweight	patients	with	metabolic	 syndrome,	
RRI	has	been	found	to	be	linked	with	increased	carotid	intima-
media	thickness,	which	is	accepted	in	turn	to	be	linked	with	upset	
endothelial	function	[11].			
Reports	so	far	have	confirmed	that	PCOS	patients	with	all	
three	criteria	have	 lower	 insulin	 sensitivity	 [10,	20].	We	 found	
that	PCOS	patients	with	all	three	criteria	have	greater	intra-renal	
and	insulin	resistance	as	well	as	more	atherogenic	dyslipidemia	
than	 the	 PCOS	 subgroup	 without	 hyperandrogenism	 and	 the	
controls.	 In	 the	 light	 of	 these	 findings,	 the	 PCOS	 subgroup	
with	 all	 three	 criteria	 seems	 to	 be	 the	 worst	 phenotype	 as	 far	
as	 cardiovascular	 risk	 is	 concerned,	while	 the	PCOS	 subgroup	
without	hyperandrogenism	appears	to	suffer	from	a	lighter	form	
of	the	illness.		
In	this	study,	we	showed	that	PCOS	phenotypic	subgroups	
are	heterogeneous	with	regard	to	the	intra-renal	resistance,	which	
shows	 the	 vascular	 effects	 of	 insulin	 resistance.	 Undoubtedly,	
a	more	 flexible	 approach	 is	 needed	 in	 the	management	 of	 the	
metabolic	 effects	 of	 PCOS.	 PCOS	 subgroups	 have	 different	
clinical	features	and	metabolic	and	cardiovascular	risk	factors	of	
different	degrees.	
Conclusions
In	conclusion,	women	with	PCOS	do	not	all	have	the	same	
metabolic	and	cardiovascular	risk	profile.	Clinical	subgroups	of	
PCOS	should	be	taken	into	consideration	when	assessing	patient	
risk.	There	is	also	a	need	for	further	studies	that	examine	the	link	
between	insulin	resistance	and	other	markers	of	atherosclerosis.	
Table II. Relationships of RRI with HOMA-IR and other study variables in all patients.
   RRI PSV Insulin HOMA-IR
Age (years) 
r ,050 -,064 ,100 ,108
p ,591 ,488 ,279 ,241
BMI (kg/m2) 
r ,555 -,174 ,635 ,616
p ,000 ,058 ,000 ,000
WHR 
r ,325 -,126 ,419 ,471
p ,000 ,171 ,000 ,000
AFC 
r ,097 -,004 ,064 ,081
p ,293 ,970 ,490 ,384
RRI 
r 1 -,335 ,703 ,665
p  ,000 ,000 ,000
PSV 
r -,335 1 -,418 -,410
p ,000  ,000 ,000
Glucose (mg/dl) 
r ,083 -,129 ,147 ,314
p ,371 ,163 ,111 ,001
Insulin (µU/mL) 
r ,703 -,418 1 ,980
p ,000 ,000  ,000
HOMA-IR 
r ,665 -,410 ,980 1
p ,000 ,000 ,000  
HDL (mg/dl) 
r -,370 ,144 -,312 -,341
p ,000 ,118 ,001 ,000
LDL (mg/dl) 
r ,244 ,051 ,299 ,265
p ,007 ,582 ,001 ,004
Triglycerides (mg/dl) 
r ,295 -,070 ,371 ,387
p ,001 ,448 ,000 ,000
Total Testosterone (µU/mL) 
r ,265 -,128 ,238 ,268
p ,004 ,164 ,009 ,003
TSH 
r ,037 ,005 -,051 -,026
p ,693 ,955 ,585 ,782
LH (mIU/mL) 
r ,013 ,037 ,021 ,035
p ,884 ,688 ,822 ,707
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